FOXP3 and Alzheimer disease: To better characterize the CD4+ CD25+ FoxP3+ Treg population in the VitD AD model, we measured the expression of various surface markers which are involved in Treg function in mice with overt AD symptoms, i.e. on day 10 of treatment.